medvi tirzepatide Medvi GLP Consumer Reports and

Medications that involve peptides would not make a successful transit of the digestive tract without modified peptides

Patients on 1 mg of semaglutide lost an average of 5.7 kg (~12.6 lbs)

Intolerable side effects significantly impairing quality of life might make treatment unsustainable

It acts on GLP-1, which reduces appetite and slows stomach emptying

While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause its views to change

After 176 weeks of treatment, only 1.3% of tirzepatide-treated patients progressed to type 2 diabetes compared to 13.3% of patients taking a placebo